CANDIDEMIA 2025 CASE REPORT FORM	tate ID: Date of	Incident Specimen Collec	tion (<i>mm-dd-yyyy</i>):	Surveillance	e Officer Initials	
Address:	''	CANDIDEMIA	2025 CASE REPORT FO	RM		
Address:	atient name:		Medical Record No	o.:		
Acc No. (incident isolate): City, State)		(1				
Address type: 1			<u> </u>			
Address type: 1			•	,		
1		(Zip Code)	Acc No. (subseq is	solate):		
Check if not a case: Reason not a case: Out of catchment area Duplicate entry Not candidemia Unable to verify address Other (specify): SURVEILLANCE OFFICER INFORMATION 1. Date reported to EIP site: 3. Was case first identified through audit? 1 Yes 0 No 9 Unknown 1 Complete 2 Pending 3 Chart Unavailable 1 Yes 0 No No DEMOGRAPHICS 8. State ID:		Long-term care facility 4	Corrections 5 Military 6	☐Homeless 7 ☐Other 8	☐Insufficient 9 ☐]Missing
Reason not a case:	none no.: ()					
Reason not a case:						
SURVEILLANCE OFFICER INFORMATION 1. Date reported to EIP site: 3. Was case first identified through audit? 1 Yes 0 No 9 Unknown 1 Complete 2 Pending 3 Chart unavailable 2. Date review completed: 4. Isolate available? 1 Yes 0 No No No No No No No						
1. Date reported to EIP site:			□Not candidemia □Unable t	to verify address Other ((specify):	
identified through audit?						
2. Date review completed: 4. Isolate available? 1	id	lentified through audit? $_{ m 1}$	i. Previous candidemia epis ☐Yes 0 ☐No 9 ☐Unknown	ode?	1 □Complete in	
DEMOGRAPHICS 10. State:		5	ia. If yes, enter state		_	
DEMOGRAPHICS 8. State ID:	1		Ds:			
8. State ID:		Tes 0N0			anavanabie	
9. Patient ID:	EMOGRAPHICS					
12. Lab ID where positive culture was identified:			11. Co	unty:		
13. Date of birth (mm-dd-yyyy):	Patient 1D:					
	2. Lab ID where positive culture w	vas identified:				
Ibs oz. OR ft in. OR in. OR 18. BM1: (record only if nt. and/or wt. is not	, ,,,,,]days 2 □mos 3 □yrs			
	 5. Weight:	17. Height:		10 DMT: (:: h	
1						Unknown
19. Race and/or Ethnicity (select all that apply):	9. Race and/or Ethnicity (select all	that apply):				
□American Indian orAlaska Native □ Middle Eastern or North African			or North African			
□Asian □Native Hawaiian orPacific Islander]Asian	☐Native Hawaiian	orPacific Islander			
□Black orAfrican American □White]Black orAfrican American	□White				
☐Hispanic or Latino ☐Unknown]Hispanic or Latino	□Unknown				
LARODATORY DATA	A DODATORY DATA					
20. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy):		ection (DISC) (mm-dd-yyy)	y):			
21. Location of Specimen Collection:	L. Location of Specimen Collection	n:				
☐ Hospital Inpatient ☐ Outpatient ☐ LTCF]Hospital Inpatient	☐ Outpatient		LTCF		
Facility ID: Facility ID: Facility ID:	Facility ID:	Facility ID:	_	Facility ID:		
☐ ICU ☐ Emergency Room ☐ LTACH						
Burn unit Clinic/Doctor's office Facility ID:			_			
□ Surgery/OR □ Dialysis center □ Autopsy □ Radiology □ Surgery □ Other	÷					
☐ Other inpatient ☐ Observational/clinical decision unit ☐ Unknown						
Other outpatient			_			
22. Candida species from initial positive blood culture (check all that apply):	2. <i>Candida</i> species from initial pos	sitive blood culture (check	all that apply):			
☐ Candida albicans (CA) ☐ Candida dubliniensis (CD) ☐ Candida, other (CO) specify:	<i>¬Candida albicans</i> (CA)	□ Candida dut	bliniensis (CD)	Candida. other (CO) sne	cifv:	
□ Candida auris (CAU) □ Candida lusitaniae (CL) □ Candida, germ tube negative/non albicans (CGN)						GN)

Public reporting burden of this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

State ID: Date of Incide		_ Date of Incider	nt Specimen Collection (<i>mm-dd-yyyy</i>):			Surveillance Officer Initials				
☐ Candida glabrata (CG) ☐ Candida parapsilosis (CP) ☐ Candida tropicalis (CT))	☐ Candida krusei (CK)☐ Candida guilliermond	dii (CGM)		☐ Candida species (CS) ☐ Pending				
		lity testing (chec	k here \square if no testing don	ne/no test repo	rts availab	le):				
Ī	Date of culture	Species	Drug	MIC		Inte	erpretatio	on]
			Amphotericin B		□s	□SDD □]I 🔲R	□NI	□ND	
	1 □CA		Anidulafungin (Eraxis)		□s	□SDD □]I □R	□NI	□ND	
	13	13 □CAU 2 □CG	Caspofungin (Cancidas)		□s	□SDD □]I □R	□NI	□ND	
			Fluconazole (Diflucan)		□s	□SDD □]I 🗆R	□NI	□ND	
		5 □CD	Flucytosine (5FC)		□s	□SDD □]I 🔲R	□NI	□ND	
		7 □CK	Itraconazole (Sporanox)		□s	□SDD □]I 🔲R	□NI	□ND	
			Micafungin (Mycamine)		□s	□SDD □]I □R	□NI	□ND	
			Posaconazole (Noxafil)		□s	□SDD □]I □R	□NI	□ND	
		Rezafungin (Rezzayo)		□s	□SDD □]I □R	□NI	□ND		
			Voriconazole (Vfend)		□s	□SDD □]I □R	□NI	□ND	
			Amphotericin B		□s	□SDD □]I □R	□NI	□ND	
		1	Anidulafungin (Eraxis)		□s	□SDD □]I 🗆R	□NI	□ND	
	13 □CAU 2 □CG	l. —	Caspofungin (Cancidas)		□s	□SDD □]I 🔲R	□NI	□ND	
		3 □CP 4 □CT 5 □CD	Fluconazole (Diflucan)		□s	□SDD □]I 🔲R	□NI	□ND	
			Flucytosine (5FC)		□s	□SDD □]I □R	□NI	□ND	
		6 □CL 7 □CK	Itraconazole (Sporanox)		□s	□SDD □]I 🗆R	□NI	□ND	
		8	Micafungin (Mycamine)		□s	□SDD □]I □R	□NI	□ND	
		10 □CGN 11 □CS	Posaconazole (Noxafil)		□s	□SDD □]I □R	□NI	□ND	
		12 ☐Pending	Rezafungin (Rezzayo)		□s	□SDD □]I □R	□NI	□ND	
			Voriconazole (Vfend)		□s	□SDD □]I □R	□NI	□ND	
24. Did	the patient have	a PCR molecular	test for <i>Candida</i> (e.g., T2)	, in the 6 days	before or t	wo days af	ter the D	ISC?		
1 ∐Yes	0 □No 9 □Unk	nown								
25a. If y	es, test type:		_							
25b. Res	ult:		_							

Version: Short Form 2024 Last Updated: 07/29/2023 Page **2** of **10**

State ID: Da	te of Incident Specimen C	collection (<i>m</i>	nm-dd-y)	<i>(YY)</i> :			Surveilla	nce Officer I	nitials	
25. Any subsequent positive (Candida blood cultures in t	he 29 days	after, no	t incl	uding t	the DISC	? 1 □Yes	0 □No 9 □	Unknov	vn
25a. If yes, provide dates of all su	ubsequent positive Candida blo	ood cultures a	and select	the s	pecies:					
Date Drawn (<i>mm-dd-yyyy</i>)	Species identified*									
	CA CAU CG [□СР □СТ	□CD [□CL	□ск	□CGM	□co:	CGN	□cs	□Pending
	□CA □CAU □CG [Пср Пст		⊐cı	□ск	Пссм	Псо∙	□сы	□cs	□Pending
										_
	□CA □CAU □CG [CL	∐CK	∐CGM	∐CO:	□CGN		Pending
	□CA □CAU □CG [□СР □СТ	□CD [□CL	□CK	□CGM	□co:	□CGN	□cs	Pending
*Attach additional MIC page if a same <i>Candida</i> species (if no AFS			m origina	ıl), if a	anothe	r <i>C. glabi</i>	<i>rata</i> (even if or	iginal was <i>C.</i>	glabra	<i>ta</i>), or if
26. Documented negative <i>Cai</i> negative culture were positive							in which no l	olood culture	es aftei	this
26a. If yes, date of negative blood	d culture:									
27. On the day of or in the 6 of colonized with a multi-drug re 1 Yes 0 No 9 Unkn 27a. If yes, specify organisms (En	esistant organism (MDRO) own	(e.g., on co	ntact pr	ecaut	ions)?	MDROs	include CRE,	CRPA, CRAB	iey wei , MRSA	re A, and VRE.
28. Additional non- <i>Candida</i> or										
1 □Yes 0 □No 9 □Unkn	own									
28a. If yes, additional organisms	(Enter up to 3 pathogens):			<i>,</i>					_	
29. Did the patient have any capply): None Unknown	of the following types of su	uspected or	confirme	ed inf	ection	related	to their <i>Cand</i>	<i>ida</i> infection	? (chec	k all that
☐Abdominal infection	☐Urinary tract infection	Pulmonary	y infection	1			□Endocarditi	S		
☐Hepatobiliary or pancreatic	☐Esophagitis	□Abscess	;				☐Septic er	nboli (specify	location):
Abscess (specify):			tion (meni	ingitis,	, brain	abscess)	☐Other (spe	cify):		
Peritonitis/peritoneal fluid	Osteomyelitis	☐Eyes								
☐ Splenic	☐Skin /wound infection	☐ Endoph☐ Chorior								
30. Was the patient known to	be colonized with <i>Candid</i>	<i>la auris</i> befo	re their o	candi	demia	diagnos	s?			
1 □Yes 0 □No 9 □Unkn						-				
MEDICAL ENCOUNTERS										
31. Was the patient hospitaliz	ed on the day of or in the	6 days after	r the DIS	C?	1 [Yes 0	□No 9 □Unl	known		
31a. If yes, Date of first admission:		Unkn	iown							
Hospital ID:	Unknown	1								
31b. Was the patient transferred 1 ☐ Yes 0 ☐ No 9 ☐ Un	•									
If yes, enter up to two transfers:										
Date of transfer:		Unknown [Date of se	econd	transfe	r:				Unknown
Hospital ID:		I	Hospital II	D:			🗆	Jnknown		

Version: Short Form 2024 Last Updated: 07/29/2023 Page **3** of **10**

State ID:	_ Date of Incident Specimen Collection (mm-dd-yyyy):	Surveillance Officer Initials
31c. Where was the patient the DISC? (<i>Check one</i>)	located prior to admission or, if not currently hospitalized, wh	nere was the patient located on the 3rd calendar day before
1 □Private residence	4 □LTACH	6 □Correctional or detention facility
2 Hospital inpatient	Facility ID:	8 Drug/alcohol rehabilitation
Facility ID:	,	10 Not born yet
3 □LTCF	5 ☐ Homeless	7 □ Other
Facility ID:		
,		9 Unknown
_	ICU in the 14 days before, not including the DISC?	
1 □Yes 0 □No 9	□Unknown	
33. Was the patient in an	ICU on the day of incident specimen collection or in the 1	13 days after the DISC?
1 □Yes 0 □No 9	□Unknown	
34. Did the patient receiv	ve dialysis or renal replacement therapy (RRT) in the 30 d	lays before the DISC, not including the DISC?
1	□Unknown	
35. Patient outcome: 1	Survived Died 3 Hospitalized > 1 year 9 U	Inknown
Date of discharge:	Date of deat	h:
	Unknown	Unknown
☐ Left against medical ad	vice (AMA)	
35a. Discharged to:		
0 ☐Not applicable (i.e. patie	ent died, or not hospitalized)	
1 □Private residence	6 ☐Homeless	
2 LTCF Facility ID:	7 Correctional or detention fac	cility
3 LTACH Facility ID:	Q □ Drug/alcohol robabilitation	
Eliteri ruelle, 15.	9 🗌 Unknown	
	any of the following classes or specific ICD-10 codes, including a specific ICD-10 cod	
	☐ B48 (other mycoses, not classified els	· _
B37 (candidiasis)	_ ` ` ` ` `	R65.2 (severe sepsis)
Specify sub-code:	` ' ' ' '	
Specify sub-code:	T80.211 (BSI due to central venous c	Specify code:
☐ P37.5 (neonatal candidias	sis)	Specify code:
37. Previous Hospitalizati	ion in the <u>90 days before</u> , not including the DISC: $1 \square Yes$	0 □No 9 □Unknown
37a. If yes, date of discharge	e: Unknown	
Facility ID:		
•	ACH in the <u>90 days before</u> , not including the DISC: $1 \square Ye$	s 0 □No 9 □Unknown
Facility ID:		
39. Overnight stay in LTC Facility ID:	CF in the 90 days before, not including the DISC: 1 Yes	0 □No 9 □Unknown
UNDERLYING CONDITION	ONS	
40. Underlying condition	ns (Check all that apply):	
☐Chronic Lung Disease	☐Liver Disease	☐Plegias/Paralysis
☐Cystic Fibrosis	☐Chronic Liver Disease	☐Hemiplegia
☐Chronic Pulmonary disea	se Ascites	□Paraplegia
☐ Chronic Metabolic Dise	<u> </u>	Quadriplegia
□ Diabetes Mellitus	Hepatic Encephalopathy	☐ Renal Disease
With Chronic Complicat		Chronic Kidney Disease
C////Stroke/TIA	·	Lowest serum creatinine:mg/DL Unknown or not done
□CVA/Stroke/TIA	☐Hepatitis C	Continuoni oi fior dolle
Version: Short Form 20	D24 Last Updated: 07/29/2023	Page 4 of 10

State ID: Date of Incide	nt Specimen Collection (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
Congenital Heart disease Congestive Heart Failure Myocardial infarction Peripheral Vascular Disease (PVD) Gastrointestinal Disease Diverticular disease Inflammatory Bowel Disease Peptic Ulcer Disease Short gut syndrome Immunocompromised Condition HIV infection AIDS/CD4 count <200 Primary Immunodeficiency Transplant, Hematopoietic Stem Cell Transplant, Solid Organ (specify):	☐Treated, in SVR ☐Current, chronic ☐Hepatitis B, acute ☐Malignancy ☐Malignancy, Hematologic ☐Malignancy, Solid Organ (non-metastatic) ☐Malignancy, Solid Organ (metastatic) ☐Neurologic Condition ☐Cerebral palsy ☐Chronic Cognitive Deficit ☐Dementia ☐Epilepsy/seizure/seizure disorder ☐Multiple sclerosis ☐Neuropathy ☐Paresis ☐Parkinson's disease	□Skin Condition □Blistering disease □Burn □Decubitus/Pressure Ulcer □Eczema □Psoriasis □Surgical Wound □Other chronic ulcer or chronic wound □Other □Connective tissue disease □Obesity or morbid obesity □Pregnant
	□ Parkinson's disease □ Spinal cord injury	

Last Updated: 07/29/2023

Page **5** of **10**

Version: Short Form 2024

State ID:	Date of Incident Specimen Collection	n (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
SOCIAL HISTORY			
41. Smoking (Check all that	apply):	42. Alcohol Abuse:	
☐None documented	□Tobacco	1 □Yes	
Unknown	☐E-nicotine delivery system	0 ☐None documented	
GOTIKIOWIT		9 □Unknown	
43. Other Substances (Che	eck all that apply): None docume	 nted □Unknown	
43. Other Substances (Che	,	Disorder (DUD/Abuse):	Mode of Delivery (Check all that apply):
☐Marijuana (other than smo	king)	DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule I (e.g		□DUD or abuse	□IDU □Non-IDU □Unknown
☐Opioid, DEA schedule II-IV	(e.g., methadone, oxycodone)	□DUD or abuse	□IDU □Non-IDU □Unknown
☐Opioid, NOS		□DUD or abuse	□IDU □Non-IDU □Unknown
☐ Cocaine		□DUD or abuse	□IDU □Non-IDU □Unknown
☐ Methamphetamine		DUD or abuse	□IDU □Non-IDU □Unknown
Other (specify):		DUD or abuse	□IDU □Non-IDU □Unknown
☐Unknown substance		□DUD or abuse	□IDU □Non-IDU □Unknown
			tment (MAT) for opioid use disorder?
1 □Yes 0 □No	8 □N/A (patient not hospitalized or did	not have DUD) 9 ∐Ur	nknown
OTHER CONDITIONS			
45. For cases ≤ 1 year of a	ge: Gestational age at birth:	wks 9 □Unknown ANI	D Birth weight: gms 9 Unknown
46. Chronic Dialysis:	Not on chronic dialysis Unknown	46a. If Hemodialysis, typ	e of vascular access:
Type: Hemodialysis] Peritoneal	☐ AV fistula/graft ☐	Hemodialysis central line Unknown
47. Surgeries in the 90 day	ys before, not including the DISC:	48. Pancreatitis in the	90 days before, not including the DISC:
☐Abdominal surgery (specify	r):	1 □Yes	
If yes: 1 ☐Open abdome	en 0 □Laparoscopic 9 □Unknown	0	
□Non-abdominal surgery (sp	ecify):	9 □Unknown	
☐No surgery			
49. Did the patient have a	ny ostomies of the gastrointestinal t	ract including ileostomy,	colostomy, etc. in the 30 calendar days before, not
including the DISC?			
1 □Yes 0 □No 9 [□Unknown		
50. Chronic Urinary Tract		50a. If yes, did the patient before, not including the	nt have any urinary tract procedures in the 90 days DISC?
1 □Yes 0 □No	9 □Unknown	1	9 □Unknown
51. Was the patient neutro	openic in the 2 calendar days before,	not including the DISC?	,
I	☐Unknown (no WBC days -2 or 0, or no o	_	
52. Did the patient have a	CVC in the 2 calendar days before, n	ot including the DISC?	
1 □Yes 2 □No 3 [☐Had CVC but can't find dates 9 ☐Unk	known	
If yes, was the central line	e in place for > 2 calendar days: $1 \square Yes$	0 □No 9 □Unkı	nown
52a. If yes, CVC type: (Check	all that apply)		
□Non-tunneled CVCs	☐Implantable ports		Other (specify):
☐Tunneled CVCs	☐Peripherally inserte	ed central catheter (PICC)	□Unknown
52b. Were <u>all</u> CVCs removed of	or changed in the 2 days before or in the	6 days after the DISC?	
1 □Yes	3 □CVC removed, but can't find d		9 ☐Unknown
2 No	5 Died or discharged before ind		the DICC2
·	midline catheter in the 2 calendar da ☐Unknown	ays perore, not including	nie pioc.

Last Updated: 07/29/2023

Page **6** of **10**

Version: Short Form 2024

State ID:	Date of Incident Specimen Collec	tion (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
54. Did the patient have DISC? None Unk		ces or other devices pres	sent in the 2 calendar days before, not including the
☐Urinary Catheter/Device	Respiratory		☐Gastrointestinal
☐Indwelling urethral	□ET/NT		Abdominal drain (specify):
Suprapubic	☐Tracheos		☐Gastrostomy
EE Did the nationt have		mechanical ventilation	, or other confirmatory test, excluding serology) from
a specimen collected in	the 90 days before the DISC or on th		, or other comminatory test, excluding serology) from
1 □Yes 0 □No	9 □Unknown		
55a. If yes, date of specime	en collection for initial positive SARS-CoV-	2 test:	
Date: 9 🗆 D	ate Unknown		
	T Case ID: None o	· ·	
•	ive systemic antibacterial medication	n in the 14 days before, n	not including the DISC?
1 □Yes 0 □No 9 □U	Inknown		
57. Did the patient recei	ive any systemic steroids in the 30 d	ays before, not including	the DISC?
1 □Yes 0 □No 9 □U	Inknown		
57a. If yes, what was the r	eason steroids were administered? (check	k all that apply)	
	as an outpatient medication prior to <i>Candida</i> DISC, during hospitaliza	tion occasiotod with condida	ancia anicada
. , -	as part of treatment/management for CO		ernia episode
☐ None of the abov	•		
58. Did the patient recei	ive total parenteral nutrition (TPN) in	n the 14 days before, not	t including the DISC?
1 □Yes 0 □No 9 □U	Inknown		
59. Did the patient recei	ive systemic antifungal medication o	n the day of or in the 13	days before the DISC?
1 ☐Yes (if Yes, fill out que	estion 67) 0 □No 9 □Unknown	l	
60. Was the patient adm	ninistered systemic antifungal medic	ation after, not including	the DISC?
1 □Yes (if Yes, fill out que	<i>estion 67)</i> 0 □No 9 □Unknown	ı	
61. If antifungal medica	ntion was not given to treat current c	andidemia infection, who	at was the reason?
1 □Patient died before cul	ture result available to clinicians	5 ☐Other reason docu	umented in medical records, specify:
2 ☐Comfort care only mea	asures were instituted	6 □Patient refused tre	eatment against medical advice
3 □Patient discharged befo	ore culture result available to clinician	9 □Unknown	
	ted culture result not clinically significant o	or	
contaminated	IF ANY ANTIFUNGAL MEDI	CATION WAS GIVEN CO	MDI ETE NEYT DAGE
	IF ANT ANTIFONGAL MEDI	CATION WAS GIVEN, CO	MPLLIE NEXT PAGE.
OTHER 62. Does the chart indicinfection?	ate that the incident specimen was c	onsidered a contaminan	t or was considered to not be indicative of true
	9 □Unknown		
		hysician on the day of th	ne DISC or within the 6 days after the DISC?
1	9	,	·
64 Did the natient have	an echocardiogram (FCHO), includi	og transthoracic (TTF) or	r transesophogeal (TEE), on the day of or 13 days
after the DISC?	an echocaralogram (Eeho), includi	ig transtitoracie (112) or	transcropinogear (122), on the day of or 15 days
1 □Yes 0 □No	9 □Unknown		
65. Did the patient have	a dilated fundoscopic eye exam on t	the day of or 13 days afte	er the DISC?
1	9 □Unknown		
66. Is case associated w	vith a known outbreak?		
1	9 □Unknown		

Version: Short Form 2024 Last Updated: 07/29/2023 Page **7** of **10**

lulafungin (any IV formulation (Amphotec, A some, etc.)=AMBIV (Eraxis)=ANF Cancidas)=CAS	Fli Is Itı	uconazole (Diflucan)=FLC ucytosine (5FC)=5FC avuconazole (Cresemba)=ISU raconazole (Sporanox)=ITC icafungin (Mycamine)=MFG	Pc Re UI	her=OTH saconazole (Noxafil)=PSC szafungin (Rezzayo)= RZF NKNOWN DRUG=UNK riconazole (Vfend)=VRC	
ANTIFUN a. Drug Abbrev	GAL MEDICATION b. First date given (mm-dd-	c. Date start unknown	d. Last date given (mm-dd-yyyy)	e. Date stop unknown	f. Indication	g. Reason for stopping (if applicable)*
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
					Prophylaxis Treatment	

Version: Short Form 2024Last Updated: 07/29/2023Page 8 of 10

State ID:	Date of I	ncident Specimen Collection	n (<i>mm-dd-yy</i>	yy): Surveillance Officer Initials
		AFCT seeks for		0
	hilibu kaakina (ab	AFST results for a		
Date of culture	Species	eck here if no testing do	MIC	
Date of culture		Drug Amphotericin B	MIC	Interpretation □S □SDD □I □R □NI □ND
	1 □CA 13 □CAU	Anidulafungin (Eraxis)		
	2 □CG			
	3 □CP 4 □CT	Caspofungin (Cancidas)		S SDD II R NI ND
	4 □CT 5 □CD	Fluconazole (Diflucan)		
	6 □CL	Flucytosine (5FC)		S SDD II R NI ND
	7 □CK	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	8 □CGM 9 □CO	Micafungin (Mycamine)		S SDD I R NI ND
	10 □CGN	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 CS	Rezafungin (Rezzayo)		□S □SDD □I □R □NI □ND
	12 Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
	1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND
	13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	5	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	6 □CL 7 □CK	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	8 □CGM	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	9	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 □CS	Rezafungin (Rezzayo)		□S □SDD □I □R □NI □ND
	12 ☐Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
ntifungal suscepti	bility testing (ch	eck here \square if no testing do	ne/no test re	ports available):
Date of culture	Species	Drug	MIC	Interpretation
	1	Amphotericin B		□S □SDD □I □R □NI □ND
	13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	5	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	6 □CL 7 □CK	Itraconazole (Sporanox)		☐S ☐SDD ☐I ☐R ☐NI ☐ND
	8 □CGM	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	9	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	10 □CGN 11 □CS	Rezafungin (Rezzayo)		□S □SDD □I □R □NI □ND
	12 Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
		Amphotericin B		□S □SDD □I □R □NI □ND
	1 □CA 13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	3 □CP	Fluconazole (Diflucan)		S SDD I R NI ND
	4 □CT 5 □CD	, ,		
	6 □CL	Flucytosine (5FC)		
		Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND

Version: Short Form 2024 Last Updated: 07/29/2023 Page **9** of **10**

State ID: Date of	Incident Specimen Collection (mm-dd	· <i>үүүү</i>):	Surveillance	e Officer Initials
7 □CK	Micafungin (Mycamine)	□S	□SDD □I □R	□NI □ND
8	Posaconazole (Noxafil)	□S	□SDD □I □R	
9	Rezafungin (Rezzayo)	□S		
11 □CS 12 □Pending	Voriconazole (Vfend)		□SDD □I □R	
12 Eli chang				

Last Updated: 07/29/2023

Page **10** of **10**

Version: Short Form 2024